CRYOPORT, INC. Provision for Loan, Lease, and Other Losses
CRYOPORT, INC. (CYRX) reported Provision for Loan, Lease, and Other Losses of $822.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProvisionForLoanLeaseAndOtherLosses · last filed 2024-03-13
- CRYOPORT, INC. provision for loan, lease, and other losses for fiscal 2023 was $822.00K, a 251.28% increase from fiscal 2022.
- CRYOPORT, INC. provision for loan, lease, and other losses for fiscal 2022 was $234.00K, a 800.00% increase from fiscal 2021.
- CRYOPORT, INC. provision for loan, lease, and other losses for fiscal 2021 was $26.00K.
| Period end | Provision for Loan, Lease, and Other Losses 12 month |
|---|---|
| 2023-12-31 | $822.00K 10-K · filed 2024-03-13 |
| 2022-12-31 | $234.00K 10-K · filed 2024-03-13 |
| 2021-12-31 | $26.00K 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |